This information is intended for members of the public in the UK only.


INFORMATION ON ELIQUIS® (APIXABAN) FOR MEMBERS OF
THE PUBLIC

This section contains reference information only.
Bristol-Myers Squibb and Pfizer are unable to provide advice on personal medical matters. Please contact your doctor or other relevant healthcare professional for specific, health-related advice and support.

ELIQUIS contains the active substance apixaban, and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.


Please click here to access the ELIQUIS (apixaban) Summary of Product Characteristics and Patient Information Leaflet, which can be found on the electronic medicines compendium (eMC).

REPORT SIDE EFFECTS

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side
effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme
at www.mhra.gov.uk/yellowcard. Side effects for this medicine should also be reported to Bristol-Myers Squibb
Medical Information on 0800 731 1736 or medical.information@bms.com. By reporting side effects, you can help provide more information on the safety of this medicine.